Streetbeat News

Earnings

KURA

Kura Oncology (NASDAQ:KURA) is scheduled to release its quarterly earnings report on February 27, 2024, with analysts expecting an EPS of $-0.55. The company's past performance shows a trend of beating EPS estimates, leading to positive stock price movements. Shares are currently trading at $20.25, reflecting a 73.15% increase over the last 52 weeks. Investors are looking forward to not only the earnings results but also the company's future guidance.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:01 pm

LPRO

Open Lending (NASDAQ:LPRO) is scheduled to release its quarterly earnings report on February 27, 2024, with an estimated EPS of $0.04. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows a significant impact of earnings performance on the stock price, with notable fluctuations following past earnings announcements. Shares of Open Lending have increased by 12.57% over the last 52 weeks, indicating a generally positive sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:01 pm

SSTI

ShotSpotter (NASDAQ:SSTI) is scheduled to release its quarterly earnings report on February 27, 2024, with an estimated EPS of $0.05. Historical data shows mixed reactions to past earnings, with the last quarter missing estimates and resulting in an 8.67% share price increase the following day. Over the last year, SSTI shares have declined by 47.95%, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:00 pm

CHWY

Deep-pocketed investors show a divided sentiment on Chewy (NYSE:CHWY), with equal bullish and bearish positions in options trading. Benzinga's tracking revealed significant activity, suggesting a price target range of $15.0 to $27.5. Chewy, a leading e-commerce pet care retailer, is currently trading at $16.26, with potential oversold conditions and an upcoming earnings release.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:00 pm

DRVN

Driven Brands Hldgs (NASDAQ:DRVN) received mixed analyst ratings over the last three months, with a shift towards a more cautious outlook. The average 12-month price target was lowered to $17.4, indicating a 17.14% decrease from the previous target. Financial performance shows challenges in revenue growth, profitability, and debt management, with recent metrics indicating a revenue decline of -4.71%, a net margin of -2.37%, and a high debt-to-equity ratio of 4.72.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:00 pm

CLSK

MARA

RIOT

Bitcoin mining stocks CleanSpark, Marathon Digital, and Riot Platforms are experiencing significant gains due to the rising price of Bitcoin, which has reached its highest level since December 2021. The surge is attributed to increased demand following the approval of spot ETFs and anticipation of April's halving event. CleanSpark's shares rose after reporting strong earnings, Riot reported all-time highs in revenues and Bitcoin production, and Marathon is expected to report earnings soon.

Portfolio Pulse from Adam Eckert

February 26, 2024 | 4:58 pm

AMZN

BRK-B

GOOG

NVDA

QQQ

SPY

TSLA

Berkshire Hathaway Inc. Class B (BRK-B) stock is up after slightly beating earnings estimates, despite Warren Buffett's concerns over high market prices and difficulty finding large companies to buy. Berkshire sits on a record $167.7B cash, with Buffett slowing down BRK-B buybacks, indicating he views the stock as expensive. The article also notes positive early trade money flows in AMZN, NVDA, TSLA, neutral in AAPL, META, MSFT, negative in GOOG, and mixed in SPY and QQQ. The momo crowd is buying stocks and oil, selling gold, with smart money inactive.

Portfolio Pulse from The Arora Report

February 26, 2024 | 4:56 pm

CLDX

Celldex Therapeutics (NASDAQ:CLDX) reported Q4 earnings with an EPS of $-0.83, missing estimates by -12.0% against an expected $-0.74. Revenue increased by $2.52 million from the same period last year. Despite missing EPS estimates last quarter, the share price increased by 8.0% the following day. Historical earnings performance shows a pattern of missed EPS estimates but varying revenue outcomes.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:55 pm

AMR

Financial analysis of Alpha Metallurgical (NYSE:AMR) options market reveals a bearish sentiment with 57% of traders showing bearish tendencies. The analysis highlighted 14 unusual trades, with a focus on a price band between $145.0 and $520.0. Notable options activity includes both bearish and bullish trades, with significant open interest and volume in calls and puts. Alpha Metallurgical, a coal mining company, is currently trading at $409.0, up 4.9%, with an anticipated earnings release in 0 days.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:45 pm

AZN

CTLT

IHE

LLY

NVO

PFE

Zealand Pharma's survodutide drug showed promising results in Phase 2 trials for MASH, heating up competition in the obesity and diabetes treatment market. Eli Lilly and Novo Nordisk, leaders with drugs like Mounjaro and Ozempic, reported strong Q4 results. The market is becoming crowded with around 70 weight loss drugs in development, including from AstraZeneca and Pfizer. Novo Nordisk acquired Catalent Inc to scale up production, while Eli Lilly launched LillyDirect for direct consumer sales. Shares of Novo and Eli Lilly have outperformed the broader pharmaceutical sector, as has the iShares U.S. Pharmaceuticals ETF.

Portfolio Pulse from Neil Dennis

February 26, 2024 | 4:31 pm